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Abstract D-K6L9 peptide is bound by phosphatidylserine
and induces necrosis in cancer cells. In our therapeutic
experience, this peptide, when administered directly into
B16-F10 murine melanoma tumors, inhibited their growth.
Cessation of therapy results, however, in tumor relapse. We
aimed at developing a combined therapy involving D-K6L9
and additional factors that would yield complete elimina-
tion of tumor cells in experimental animals. To this
purpose, we employed glycyrrhizin, an inhibitor of
HMGB1 protein, BP1 peptide and interleukin (IL)-12.
Glycyrrhizin or BP1, when combined with D-K6L9,
inhibits growth of primary tumors only during the period of
their administration. A long-term tumor growth inhibitory
effect was obtained only in combining D-K6L9 with IL-12.
At 2 months following therapy cessation, 60 % of animals
were alive. Prolonged survival was noted in mice bearing
B16-F10 tumors as well as in mice bearing C26 colon
carcinoma tumors.
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B16-F10 Murine melanoma cells
C26 Colon carcinoma cell
CSC Cancer stem cells
HMGB1 High-mobility group box-1 protein
NK Natural killer cells
VEGR Vascular-endothelial growth receptor
PlGF Placenta growth factor
IL-12 Interleukin-12
PBS- Physiological buffered saline
RPMI 1640 Cell culture medium
Introduction
Peptides used in anticancer therapy kill cancer cells by
destroying their cell or mitochondrial membranes. D-K6L9
is an example of cell membrane-acting peptide which
triggers necrosis of cancer cells (Papo et al. 2004).
D-K6L9 is a molecule in which 1/3 of its natural ami-
noacid sequence has been replaced with diastereoisomers.
Introduction of D aminoacids increases stability of this
peptide in other organisms as it makes proteolysis more
difficult and increases peptide selectivity (Papo et al.
2004). D-K6L9 features both hydrophobic aminoacids
(leucine) and hydrophilic ones (lysine), which make it an
amphipathic molecule. In aqueous solutions, this peptide
does not preserve an ordered secondary structure, whereas
after attachment to the lipid bilayer it adopts a-helical
conformation (Papo and Shai 2003). It is preferentially
bound by membranes rich in negatively charged acidic
phospholipids (Papo et al. 2004, 2006), an augmented
number of which are found in cancer cell membranes
(Mader and Hoskin 2006). The peptide is bound by phos-
phatidylserine present in the outer membrane of the bilayer
(Papo et al. 2006). The peptide is bound until it reaches
threshold concentration upon which the membrane is
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depolarized and perforated causing cell death (Papo et al.
2004).
Therapeutic use of necrosis-triggering agents has its
advantages and limitations. Among the most important
factors released from necrotized cells is HMGB1 protein
(Ellerman et al. 2007; Tang et al. 2011). Extracellular
HMGB1 mediates chronic inflammatory condition, for-
mation of new tumor microenvironment and angiogenesis.
In other words, it facilitates tumor regrowth (Campana
et al. 2008; Tang et al. 2010; Yang et al. 2005). On the
other hand, inflammatory condition induced by HMGB1
and stimulation of antigen-presenting cell (APC) matura-
tion can trigger immune response against cancer cells
(Rovere-Querini et al. 2004; Zhu et al. 2010).
We tried to develop a combination therapy that would
involve, besides D-K6L9, also other factors that would
together totally destroy or inhibit B16-F10 melanoma
tumors in experimental animals. Since surviving cancer
cells and released HMGB1 protein can be responsible for
tumor relapse, the proposed therapy involved factors that
destroy the remnant cancer cells and that inhibit HMGB1.
HMGB1 inhibitors comprise specific antibodies,
HMGB1 protein A box (Wang et al. 2012; Yang and
Tracey 2010) or low-molecular compounds such as gly-
cyrrhizin which inhibits HMGB1 following its release into
extracellular matrix (Smolarczyk et al. 2012).
BP1 peptide binds to Flt-1 (VEGR1) receptor, thus
blocking the attachment of vascular endothelial growth
factor and placenta growth factor (PlGF). Inability of PlGF
protein to bind to Flt-1 receptors found on the surface of
cancer cells inhibits the latter’s motility and may affect the
formation of metastases (Taylor and Goldenberg 2007).
This peptide can also act effectively upon tumor endothe-
lial cells possessing Flt-1 receptor (Tarallo et al. 2010).
BP1 peptide has both anticancer properties (it inhibits
proliferation of cancer cells) and is antiangiogenic.
Another therapeutic solution involves reinforcement of
the immune system by applying interleukin (IL)-12. This
cytokine activates secretion of interferon c which, in turn,
activates cytotoxic T lymphocytes and natural killer (NK)
cells (Del Vecchio et al. 2007; Luedke et al. 2012; Uemura
et al. 2010). Additionally, IL-12 inhibits angiogenesis, and
formation of novel blood vessels (He et al. 2012; Rakh-
milevich et al. 2004).
Materials and Methods
Plasmid pBCMGSNeo/IL-12
Plasmid pBCMGSNeo carrying a gene encoding murine
IL-12 was obtained from Prof. H. Yamamoto (Osaka
University, Japan). Murine IL-12 gene is composed of two
subunits: p35 and p40 connected by cassette IRES. Gene of
IL-12 cloned into BCMGSneo (so-called Karasuyama’s
expression vector), under the control of cytomegalovirus.
Plasmid preparations were isolated using QIAGEN-Endo
Free Giga Kit (Qiagen GmbH, Hilden, Germany).
Cell Culture
Murine melanoma B16-F10 and murine colon cancer C26
cells (ATCC) were propagated in RPMI 1640 supple-
mented with 10 % fetal bovine serum. Cell cultures were
maintained in a standard 37 C/5 % CO2 incubator. Cells
were passaged every 2–3 days.
Animals
Mice (6- to 8-week-old C57Bl/6 and BALB/c females)
were from own animal facility. Consent for work with
animals was obtained from the Local Ethics Commission
(Silesian Medical University in Katowice).
DNA Fragmentation Studies: TUNEL Test
The studies were accomplished with In Situ Cell Death
Detection Kit, TMR red (Roche Diagnostic GmbH, Ger-
many). The tests were performed using gelatin-coated
8-well Chamber Slide plates. Aliquots of 2 9 104 B16-F10
cells per well were seeded in 250-lL culture medium.
After 24 h, the medium was replaced with: 10, 20, 40 lg
D-K6L9 peptide or fresh medium.
Following a 3-h incubation, the treated cells were fixed
with 4 % paraformaldehyde. Next, the specimens were
incubated on ice for 2 min with 0.1 % Triton X-100.
Positive control cells were digested with 200 lL DNase
solution (10 min at 37 C). A mixture of fluorescein-
labeled nucleotides and TdT enzyme was then added to the
wells. After 1-h incubation at 37 C, the specimens were
embedded in glycerogel and observed using a Nikon
Eclipse 80i fluorescence microscope (k = 540 nm).
Micrographs were taken using NISElements AR image
analysis software.
Hematoxylin and Eosin Staining
D-K6L9 peptide was injected intratumorally three times.
Each time the treated mice received 100 lg D-K6L9
peptide in 100 lL physiological buffered saline (PBS-).
Control mice were injected three times with PBS-
(100 lL per animal). Tumors were excised 24 h post-
last injection. The collected material was fixed in 10 %
formalin and embedded in paraffin. Five-lm-thick sec-
tions were then routinely stained with hematoxylin and
eosin.
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Immunohistochemical Identification of HMGB1
Protein in B16-F10 and C26 Tumors Following D-K6L9
Peptide Administration
Tumors were excised 24 h following D-K6L9 peptide
administration. The collected material was fixed with 10 %
formalin, paraffin-embedded and cut into 5-lm-thick sec-
tions. The latter were deparaffinized and hydrated. Next,
they were incubated with 0.3 % H2O2 and boiled with
citrate buffer (10 mM; pH 6.0). Blocking of unspecific sites
was achieved with 2.5 % horse serum. The sections were
incubated for 1 h at RT using a primary rabbit anti-
HMGB1 antibody [0.7 mg/mL; dilution 1:100; (Abcam,
Cambridge, UK)] and with secondary horse anti-rabbit
antibody conjugated to horseradish peroxidase (EC
1.11.1.7) from ImmPRESSTM REAGENT Anti-Rabbit Ig
kit (Vector, USA). Next, the specimens were incubated
with diaminobenzidine (DAB) from ImmPACTTM DAB
kit. Brown-colored product was obtained as a result of
enzymatic reaction. Finally, the specimens were dehy-
drated and were embedded using VectaMountTM.
Animal Therapy Using D-K6L9 Peptide
and Glycyrrhizin
C57Bl/6 mice were injected subcutaneously with 2 9 105
B16-F10 melanoma cells. On the seventh and eighth day
following inoculation, a 100 lg aliquot of D-K6L9 peptide
was injected intratumorally (in 100 lL PBS-), whereas
glycyrrhizin was injected intraperitoneally (2 mg/400 lL
PBS-). For the subsequent 4 days, only glycyrrhizin was
administered. The experiment was repeated twice.
Animal Therapy Using D-K6L9 and BP1 Peptides
C57Bl/6 mice were injected subcutaneously with 2 9 105
B16-F10 melanoma cells. On the seventh and eighth day
following inoculation, a 100 lg aliquot of D-K6L9 peptide
was injected intratumorally (in 100 lL PBS-). For the
subsequent 3 days, BP1 peptide (in 100 lL H2O) was
administered intratumorally. The experiment was repeated
twice.
Animal Therapy with D-K6L9 Peptide
and pBCMGSNeo/IL-12
C57Bl/6 or BALB/c mice were injected subcutaneously
with 2 9 105 B16-F10 or C26 cells. On the seventh and
eighth day following inoculation, a 100 lg aliquot of
D-K6L9 peptide was injected intratumorally (in 100 lL
PBS-). For the subsequent 9 or 10 days pBCMGSNeo/
IL-12 only was administered intratumorally (50 lg in
100 lL PBS-). Control group mice received only
plasmid DNA BCMGSNeo (empty plasmid), pBCMGS-
Neo/IL-12, D-K6L9 peptide, pBCMGSNeo (empty
plasmid) with D-K6L9 peptide or PBS
- (doses and timing
as in experimental groups). Plasmid DNA BCMGSNeo is
the carrier of the therapeutic gene IL-12. To exclude the
therapeutic effect of empty vector, pBCMGSNeo created
two groups of control mice treated with: a combination of
peptide and pBCMGSNeo (empty vector) and alone
pBCMGSNeo (empty vector). The experiment was
repeated three times.
Determination of CD8?, CD4? and NK Cell Numbers
in B16-F10 Melanoma Tumors During Therapy with D-
K6L9 Peptide and pBCMGSNeo/IL-12
B16-F10 tumor material was collected for FACS analysis
and single-cell suspension obtained with digestion mixture
[0.5 mg/mL collagenase A, (Sigma Aldrich, MO, USA);
0.2 mg/mL hyaluronidase type V, (Sigma Aldrich, MO,
USA); 0.02 mg/mL DNase I, (Roche Diagnostic GmbH,
Germany); per each 0.25 g of tumor tissue). Red blood
cells were lysed using 0.15 M ammonium chloride solution
(Sigma Aldrich, MO, USA)]. Dead cells were removed by
centrifugation on Lympholyte-M gradients (Cedarlane,
Canada). Level of T lymphocytes was determined in
homogenous single-cell suspension. To identify the sub-
populations of T lymphocytes, the following antibodies
were used: PE-CyTM7-CD3e, PE-CD4 and FITC-CD8a
(BD, Franklin Lakes, NJ, USA). NK cells were identified
with an anti-mouse CD49b antibody (Biosciences, CA,
USA). Gate parameters dividing negative from positive
cells were chosen based on isotype antibody control probes
(Jarosz et al. 2013).
Statistical Analysis
Differences between groups were determined by applying
ANOVA followed by the Tukey’s post hoc test. A p value
lower than 0.05 was considered statistically significant.
Results
D-K6L9 Peptide Does Not Cause DNA Fragmentation
(TUNEL Test)
TUNEL test was performed on B16-F10 melanoma cells
subjected to 3-h incubation with three different concen-
trations of D-K6L9 peptide (10, 20 or 40 lM), DNase
(positive control) and on untreated cells (negative control).
Positive control cells showed intense red fluorescence, thus
confirming DNA fragmentation. Cells treated with D-K6L9
peptide, similarly as negative control cells, did not display
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fluorescence. This shows that the examined peptide does
not cause fragmentation at the times that have been studied
(Fig. 1).
D-K6L9 Peptide Increases Necrotic Regions in B16-F10
and C26 Tumors and Triggers HMGB1 Release
Sections from D-K6L9 peptide-treated tumors were stained
to show HMGB1 protein presence. As a result of treatment
with this peptide, HMGB1 was released into cytoplasm,
unlike in controls where the protein is confined to cell
nucleus (Fig. 2).
D-K6L9 Peptide and Glycyrrhizin Combination Inhibits
Growth of B16-F10 Melanoma Tumors but Does Not
Prolong Animal Survival
D-K6L9 peptide combined with glycyrrhizin inhibits the
growth of B16-F10 melanoma tumors as opposed to
control groups of animals treated with peptide or gly-
cyrrhizin only (Fig. 3). After cessation of therapy,
tumor growth was resumed. Inhibition of tumor growth
did not extend survival of the treated animals (data not
shown).
D-K6L9 and BP1 Peptide Combination Inhibits Growth
of B16-F10 Melanoma Tumors but Does Not Prolong
Animal Survival
D-K6L9 and BP1 peptide combination inhibits the growth
of B16-F10 melanoma tumors as opposed to control groups
of animals treated only with either peptide (Fig. 4). After
cessation of therapy, tumor growth was resumed. Inhibition
of tumor growth did not extend survival of the treated
animals (data not shown).
D-K6L9 Peptide Combined with IL-12 Inhibits Growth
of B16-F10 Melanoma and C26 Murine Colon
Carcinoma Tumors and Prolongs Animal Survival
D-K6L9 combined with pBCMGSNeo/IL-12 does inhibit
the growth of B16-10 melanoma tumors as compared to
control mice treated with PBS-, pBCMGSNeo (empty
vector) pBCMGSNeo/IL-12, pBCMGSNeo (empty
plasmid) with D-K6L9 peptide or D-K6L9 only (Fig. 5a).
In 60 % of cases, significant extension of survival
period for combination treatment was observed
(Fig. 5b). The increase in survival time of mice was
associated with a complete loss of primary tumors
(Fig. 5d). Similar effect was observed for C26 murine
colon carcinoma tumors (Fig. 6a). In 50 % of cases,
significant extension of survival period for combination
treatment was observed (Fig. 6b). The increase in sur-
vival time of mice was associated with a complete loss
of primary tumors (Fig. 6d). This effect was observed
even after 2 months following conclusion of therapy;
mice were alive without any visible foci of B16-F10
melanoma tumors.
Combination of D-K6L9 Peptide with pBCMGSNeo/IL-
12 Causes Increase in the Number of CD8?, CD4?
and NK Cells in B16-F10 Tumors
Mice treated with D-K6L9 peptide and pBCMGSNeo/IL-
12 combination showed a significantly increased levels
of tumor infiltrating CD8? T lymphocytes and NK cells
(Fig. 7). However, increases in the number of infiltrating
cells CD4? were not observed (Fig. 7). Animals treated
with pBCMGSNeo (empty vector), pBCMGSNeo
(empty plasmid) with D-K6L9, pBCMGSNeo/IL-12,
peptide alone also showed increased numbers of T
Fig. 1 Identification of DNA fragmentation using TUNEL test. Test
was accomplished using three parallel cell cultures: untreated cells
(negative control), DNase-treated cells (positive control), peptide-
treated cells (10, 20, 40 lM D-K6L9). Red fluorescence reflecting
DNA fragmentation was found only in positive control. Objective
lens magnification 910
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lymphocytes and NK cells but not to the same degree as
in mice subjected to combinatory treatment. The latter
clearly activates both specific and nonspecific immune
response.
Discussion
Peptides are among agents intensively investigated for
anticancer properties. They show several advantages, such
Fig. 2 Immunohistochemical
assessment of B16-F10 and C26
tumors following therapy with
D-K6L9 peptide. Micrographs
shows staining of control
tumors a, c, e, g (injected with
PBS-) and b, d, f, h tumors
injected with D-K6L9 peptide.
Hematoxylin and eosin staining:
a, b B16-F10 and c, d C26.
Necrotic areas visible in
sections derived from tumors
treated with the peptide.
Objective lens magnification
910. Identification of HMGB1:
e, f B16-F10 and g, h C26.
Brown-colored staining
represents HMGB1 protein, cell
nuclei are stained blue
(hematoxylin). In control
tumors, HMGB1 protein is
present mainly in cell nuclei
(yellow arrows). In tumors
injected with D-K6L9 peptide,
HMGB1 is present outside of
cell nuclei and in extracellular
space (red arrows). Red line
indicates the border between the
area of necrosis and the
remaining tissue area. Objective
lens magnification 940
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as ease of synthesis, high degree of tumor tissues pene-
tration or low immunogenicity. Among disadvantages is
their relatively short half-time in circulation (Smolarczyk
et al. 2009).
A synthetic D-K6L9 peptide selectively destroys cancer
cells by damaging membrane structures (Papo et al. 2003).
This leads to necrotic type of cell death (Papo et al. 2004).
Such a mechanism of cell death following exposure to
this peptide can be inferred from lack of DNA
fragmentation or lack of active caspase 3 (unpublished
results), which confirms observations made by Papo et al.
(2004).
In our experiments involving B16-F10 murine melanoma
and C26 colon carcinoma tumors, we observed inhibited
tumor growth (compared to control) only during therapy
with the peptide. Papo et al. (2004, 2006) showed inhibitory
effect of the peptide using 22RV1 and CL1 prostate tumor,
as well as MDA-MB-231 breast tumor models.
Fig. 3 Effect of D-K6L9 peptide combination with glycyrrhizin on
growth of B16-F10 murine melanoma tumors. On days 7 and 8
following inoculation of mice with B16-F10 cells, the animals were
injected intratumorally with D-K6L9 peptide (100 lg/100 lL) and
intraperitoneally with 2 mg glycyrrhizin. Next, for four consecutive
days only glycyrrhizin was administered. Animals in control groups
received D-K6L9 peptide, glycyrrhizin and PBS
- in same time
sequences as those treated with combination therapy. Each group
consisted of five animals. Differences in tumor volumes between mice
that received D-K6L9 peptide and mice that received peptide and
glycyrrhizin were statistically significant (*p \ 0.009 Tukey post hoc
analysis after ANOVA) on day 17 of the therapy
Fig. 4 Effect of D-K6L9 peptide combination with BP1 peptide on
growth of B16-F10 murine melanoma tumors. On days 7 and 8
following inoculation of mice with B16-F10 cells, the animals were
injected intratumorally with D-K6L9 peptide (100 lg/100 lL). Next,
for three consecutive days only BP1 peptide (100 lg/100 lL) was
administered. Animals in control groups received D-K6L9 peptide,
BP1 peptide and PBS- in same time sequences as those treated with
combination therapy. Each group consisted of five animals. Differ-
ences in tumor volumes between mice that received D-K6L9 peptide
or BP1 peptide and mice that received both peptides were statistically
significant (*p \ 0.02 Tukey post hoc analysis after ANOVA) on day
14 of the therapy
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Following D-K6L9 peptide administration, we observed
necrosis in tumor tissue as well as release of HMGB1
protein into extracellular space. The released HMGB1
activates division of surviving cancer cells, maintains
inflammatory condition, stimulates the formation of tumor
microenvironment towards angiogenesis. It thus contrib-
utes to sustained tumor growth (Smolarczyk et al. 2012;
Tang et al. 2010). On the other hand, inflammatory con-
dition induced by HMGB1 and stimulation of APC can be
of significance for triggering specific immune response
directed against cancer cells (Zhu et al. 2010). Numerous
data have shown that tumor relapse is mediated by sur-
viving cancer cells or cancer stem cells (CSC) (Baguley
2006; Diaz and Leon 2011). Despite the fact that CSCs
constitute only a small percent of all cancer cells in a
tumor, they are CSCs that are responsible for tumor chemo-
and radioresistance (Bourguignon et al. 2008; Diaz and
Leon 2011; Diehn et al. 2009; Holtz et al. 2005; Nandi
Fig. 5 Effect of D-K6L9
peptide combination with IL-12
on growth of B16-F10 murine
melanoma tumors and survival
of the treated mice. On days 7
and 8 following inoculation of
mice with B16-F10 cells, the
animals were injected
intratumorally with D-K6L9
peptide (100 lg/100 lL). Next,
for nine consecutive days,
pBCMGSNeo plasmid (50 lg/
100 lL PBS-) carrying IL-12
gene was administered
intratumorally. Mice in control
groups received pBCMGSNeo
(empty vector), pBCMGSNeo
(empty plasmid) with D-K6L9,
pBCMGSNeo/IL-12, D-K6L9
peptide or PBS- in same time
sequences as those treated with
combination therapy. Each
group consisted of five animals.
a Combined therapy
D-K6L9 ? pBCMGSNeo/IL-
12; tumor growth vs. time.
b Combined therapy
D-K6L9 ? pBCMGSNeo/IL-
12; animal survival. *p \ 0.003
Tukey post hoc analysis after
ANOVA. Images of tumors
were performed in the 13th day
of therapy. c Control group
D-K6L9; d combined therapy
D-K6L9 ? pBCMGSNeo/IL-12
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et al. 2008; Shafee et al. 2008). This is explained by great
resistance to apoptosis, elevated levels of repair proteins
and ABC-type proteins mediating removal of toxins (Eyler
and Rich 2008; Hirschmann-Jax et al. 2004).
It has been believed that effective therapy must lead to
complete eradication of CSC (Blagosklonny 2005; Bonavia
et al. 2011; Tang 2012). To achieve this, drugs are used
that act independently of cell cycle (Diehn et al. 2009;
Massard et al. 2006; Morrison et al. 2011), along with ABC
protein inhibitors (Dean et al. 2005; Dylla et al. 2008;
Ginestier et al. 2007) and immunotherapy (Cioffi et al.
2012; Lai et al. 2012; Ning et al. 2012; Parmiani et al.
2007; Pietra et al. 2009). A more promising strategy,
however, consists of acting upon CSC niche which
Fig. 6 Effect of D-K6L9
peptide combination with IL-12
on growth of C26 colon
carcinoma tumors and survival
of the treated mice. On days 7
and 8 following inoculation of
mice with C26 cells, the animals
were injected intratumorally
with D-K6L9 peptide (100 lg/
100 lL). Next, for 10
consecutive days, pBCMGSNeo
plasmid (50 lg/100 lL PBS-)
carrying IL-12 gene was
administered intratumorally.
Mice in control groups received
pBCMGSNeo/IL-12, D-K6L9
peptide or PBS- in same time
sequences as those treated with
combination therapy. Each
group consisted of five animals.
a Combined therapy
D-K6L9 ? pBCMGSNeo/IL-
12; tumor growth vs. time.
b Combined therapy
D-K6L9 ? pBCMGSNeo/IL-
12; animal survival. *p \ 0.002
Tukey post hoc analysis after
ANOVA. Images of tumors
were performed in the 13th day
of therapy. c Control group
D-K6L9; d combined therapy
D-K6L9 ? pBCMGSNeo/IL-12
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includes endothelial cells forming tumor blood vasculature,
macrophages, fibroblasts and immune system cells (Bagu-
ley 2006; Calabrese et al. 2007). To inhibit tumor relapse,
two solutions are possible. First involves blocking HMGB1
activity which is conducive towards tumor growth. Second
solution consists of enhancing immune system response
directed against therapy-surviving cancer cells and CSC.
Our study was an attempt to develop a combination
therapy involving D-K6L9 peptide and agents that might
strengthen its action. To achieve this, we used the fol-
lowing drugs: glycyrrhizin (an inhibitor of HMGB1), BP1
peptide (angiogenesis inhibitor) and IL-12 (a cytokine
having immunostimulatory properties).
Glycyrrhizin administered intraperitoneally to mice
previously treated with a peptide only inhibited growth of
B16-F10 melanoma and C26 colon carcinoma tumors. A
similar effect was observed when using a combination of
glycyrrhizin with CAMEL peptide, which also triggers cell
necrosis (Smolarczyk et al. 2010, 2012). In most likelihood
tumor relapse that we observed following cessation of
therapy was mediated by surviving cancer cells or CSC.
Combination of glycyrrhizin with D-K6L9, as with
CAMEL, is not very efficient. Irrespective of peptide used
to induce necrosis, blocking HMGB1 only proved insuffi-
cient. To totally inhibit tumor growth, it is necessary to
eliminate the remaining surviving cancer cells.
We further tested BP1 peptide which has both anticancer
properties (it inhibits growth of cancer cells) and acts as an
antiangiogenic (by inhibiting angiogenesis activated by
HMGB1). In our opinion, due to its dual mode of action,
this peptide matched very well the assumptions behind our
combination strategy with D-K6L9. We observed inhibition
of tumor growth only during the treatment, after which
tumors invariantly regrew. Similarly, like in the case of
glycyrrhizin, surviving cancer cells or CSCs, not reached
by BP1, are responsible. Since both therapies aimed at
inhibiting activity of HMGB1 proved not very effective,
we decided to check the combination involving D-K6L9
peptide and IL-12. The latter cytokine activates T lym-
phocytes and NK cells which infiltrate tumor mass and
tissues in its vicinity and destroy cancer cells (Del Vecchio
et al. 2007; Uemura et al. 2010).
Combination of D-K6L9 and IL-12 inhibits tumor
growth and extends survival of the treated animals. In ca.
60 % of mice that harbored B16-F10 melanoma tumors
and in 75 % of mice with C26 colon carcinoma tumors,
total disappearance of tumors was observed.
A similar effect was observed when combining CAMEL
peptide and plasmid DNA carrying IL-12 gene, where
tumors disappeared in 60 % of mice bearing B16-F10
melanoma tumors (Smolarczyk et al. 2010). IL-12 combi-
nation with drugs that cause necrotic tumor cell death
(CAMEL, D-K6L9) seems to be the best therapeutic option.
IL-12 enhances response of the immune system, and acti-
vates NK cells to destroy residual tumor cells after
treatment which are responsible for tumor re-growth. In
mice that were treated with combination therapy involving
D-K6L9 and IL-12, infiltration of CD4
?, CD8? and NK
Fig. 7 Level of T lymphocytes and NK cells in B16-F10 murine
melanoma tumors treated with combination of D-K6L9 peptide and
IL-12. Analyzed tumor material was collected 24 h from last
administration of treatment agent (PBS-, pBCMGSNeo (empty
plasmid), pBCMGSNeo (empty plasmid) with D-K6L9, pBCMGS-
Neo/IL-12 or D-K6L9). PBS
- denotes two administrations of PBS-;
D-K6L9—two administrations of peptide; pBCMGSNeo—six
administrations of empty vector; pBCMGSNeo/IL-12—six adminis-
trations of plasmid DNA; D-K6L9 ? pBCMGSNeo/IL-12—two
administrations of peptide and six administrations of pBCMGSNeo/
IL-12 plasmid DNA. Bars represent averages 7–8 tumors. ANOVA:
*p \ 0.027 D-K6L9 ? pBCMGSNeo/IL-12/D-K6L9 ? pBCMGSNeo;
**p\ 0.049 D-K6L9 ? pBCMGSNeo/IL-12/D-K6L9 ? pBCMGSNeo
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cells was confirmed. Combination peptide with BP1 or
glycyrrhizin only inhibits tumor regrowth by inhibiting
angiogenesis. This is the reason why only temporary
inhibition of tumor growth is observed after cessation of
therapy. Cancer cells remaining alive after treatment with
the peptide are responsible for this growth and are resistant
to anti-angiogenic therapy. Therapeutic approach involving
the use of anti-angiogenic therapy after radically destroy-
ing the tumor is ineffective.
IL-12 has pleiotropic properties: activates specific and
non-specific response of the immune system but also has
anti-angiogenic properties (Kilinc et al. 2006; Nanni et al.
1998). The use of IL-12 in combination with peptide not
only inhibits angiogenesis but most importantly destroys
survivors’ cancer cells, responsible for tumor regrowth.
Effective cancer therapy should be based on a number of
therapeutic solutions, for example, anti-angiogenic or an-
tivascular therapy, but should essentially include
immunotherapy.
To conclude, a therapeutic strategy consisting of joined
administration of D-K6L9 peptide that induces necrosis of
cancer cells with a cytokine activating immune system
cells (IL-12) proved highly effective in inhibiting growth
of two types of experimental tumors.
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